Adaptive Biotechnologies (ADPT) Financials

$8.80 -0.01 (-0.06%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$8.81 +0.00 (+0.05%)

As of 05/7/2025 07:56 PM Eastern

Annual Income Statements for Adaptive Biotechnologies

This table shows Adaptive Biotechnologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-43	-46	-70	-146	-207	-200	-225	-159
Consolidated Net Income / (Loss)	-43	-46	-69	-146	-207	-200	-225	-160
Net Income / (Loss) Continuing Operations	-43	-46	-69	-146	-207	-200	-225	-160
Total Pre-Tax Income	-43	-46	-69	-146	-207	-200	-225	-160
Total Operating Income	-44	-50	-78	-153	-209	-200	-227	-163
Total Gross Profit	0.01	36	63	76	105	127	95	107
Total Revenue	16	56	85	98	154	185	170	179
Operating Revenue	16	56	85	98	154	185	170	179
Total Cost of Revenue	16	20	22	23	49	58	76	72
Operating Cost of Revenue	16	20	22	23	49	58	76	72
Total Operating Expenses	44	86	141	229	314	328	322	269
Selling, General & Admin Expense	16	20	30	50	75	89	84	73
Marketing Expense	17	24	38	61	95	96	89	85
Research & Development Expense	32	39	71	116	142	142	122	103
Amortization Expense	1.69	1.70	1.70	1.70	1.70	1.70	1.70	1.70
Impairment Charge	-	-	-	-	0.00	0.00	25	7.21
Total Other Income / (Expense), net	1.64	3.31	9.79	6.59	1.67	-0.18	1.73	2.95
Interest Expense	-	-	-	0.00	0.00	4.24	14	12
Interest & Investment Income	1.64	3.31	9.79	6.59	1.67	4.06	16	15
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	0.00	0.00	-0.02	-0.18	-0.05	-0.10
Basic Earnings per Share	($3.50)	($3.67)	($1.01)	($1.11)	($1.48)	($1.40)	($1.56)	($1.08)
Weighted Average Basic Shares Outstanding	12.20M	12.63M	69.17M	131.22M	140.35M	142.52M	144.38M	147.10M
Diluted Earnings per Share	($3.50)	($3.67)	($1.01)	($1.11)	($1.48)	($1.40)	($1.56)	($1.08)
Weighted Average Diluted Shares Outstanding	12.20M	12.63M	69.17M	131.22M	140.35M	142.52M	144.38M	147.10M
Weighted Average Basic & Diluted Shares Outstanding	12.20M	12.63M	69.17M	131.22M	140.35M	143.23M	145.09M	148.58M

This table shows Adaptive Biotechnologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-45	-40	-58	-48	-50	-69	-48	-46	-32	-34
Consolidated Net Income / (Loss)	-45	-40	-58	-48	-50	-69	-48	-46	-32	-34
Net Income / (Loss) Continuing Operations	-45	-40	-58	-48	-50	-69	-48	-46	-32	-34
Total Pre-Tax Income	-45	-40	-58	-48	-50	-69	-48	-46	-32	-34
Total Operating Income	-45	-39	-57	-48	-51	-71	-49	-47	-33	-34
Total Gross Profit	33	39	19	31	19	26	24	24	30	29
Total Revenue	48	55	38	49	38	46	42	43	46	47
Operating Revenue	48	55	38	49	38	46	42	43	46	47
Total Cost of Revenue	15	17	19	18	19	20	18	19	17	18
Operating Cost of Revenue	15	17	19	18	19	20	18	19	17	18
Total Operating Expenses	78	78	76	79	70	97	73	71	62	63
Selling, General & Admin Expense	21	22	21	22	20	21	20	18	17	18
Marketing Expense	22	24	22	24	20	22	22	20	21	22
Research & Development Expense	36	31	33	32	29	29	30	25	24	23
Amortization Expense	0.43	0.43	0.42	0.42	0.43	0.43	0.42	0.42	0.43	0.43
Total Other Income / (Expense), net	0.11	-0.98	-0.51	0.01	0.63	1.60	1.23	1.07	0.54	0.12
Interest Expense	0.65	3.59	3.53	3.61	3.65	3.01	2.99	2.70	2.94	2.95
Interest & Investment Income	0.77	2.60	3.02	3.61	4.28	4.61	4.22	3.77	3.47	3.07
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.04	-0.04	-0.00	-0.00	-0.03	-0.03	-0.03	-0.03	-0.03	-0.03
Basic Earnings per Share	($0.32)	($0.27)	($0.40)	($0.33)	($0.35)	($0.48)	($0.33)	($0.31)	($0.22)	($0.22)
Weighted Average Basic Shares Outstanding	142.93M	142.52M	143.51M	144.40M	144.70M	144.38M	145.79M	147.41M	147.52M	147.10M
Diluted Earnings per Share	($0.32)	($0.27)	($0.40)	($0.33)	($0.35)	($0.48)	($0.33)	($0.31)	($0.22)	($0.22)
Weighted Average Diluted Shares Outstanding	142.93M	142.52M	143.51M	144.40M	144.70M	144.38M	145.79M	147.41M	147.52M	147.10M
Weighted Average Basic & Diluted Shares Outstanding	143.01M	143.23M	144.31M	144.65M	144.77M	145.09M	147.37M	147.47M	147.58M	148.58M

This table details how cash moves in and out of Adaptive Biotechnologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	52	-30	44	27	16	-49	-24	-17
Net Cash From Operating Activities	-35	-32	205	-150	-193	-184	-156	-95
Net Cash From Continuing Operating Activities	-35	-32	205	-150	-193	-184	-156	-95
Net Income / (Loss) Continuing Operations	-43	-46	-69	-146	-207	-200	-225	-160
Consolidated Net Income / (Loss)	-43	-46	-69	-146	-207	-200	-225	-160
Depreciation Expense	4.10	4.30	6.09	6.77	12	19	21	18
Amortization Expense	2.04	0.49	-2.77	2.48	8.93	2.44	-7.49	-6.51
Non-Cash Adjustments To Reconcile Net Income	7.31	11	16	28	50	66	102	71
Changes in Operating Assets and Liabilities, net	-5.48	-1.72	255	-41	-57	-72	-46	-17
Net Cash From Investing Activities	36	0.74	-482	-117	181	2.91	130	78
Net Cash From Continuing Investing Activities	36	0.74	-482	-117	181	2.91	130	78
Purchase of Property, Plant & Equipment	-2.42	-6.30	-11	-19	-62	-16	-11	-3.66
Purchase of Investments	-125	-147	-884	-695	-317	-279	-430	-244
Sale and/or Maturity of Investments	164	154	414	597	560	298	570	326
Net Cash From Financing Activities	50	1.25	320	294	27	132	2.25	0.24
Net Cash From Continuing Financing Activities	50	1.25	320	294	27	132	2.25	0.24
Repurchase of Common Equity	0.00	0.00	-4.99	-0.32	0.00	0.00	0.00	0.00
Issuance of Common Equity	0.00	0.00	321	272	0.00	0.00	0.00	0.00
Other Financing Activities, net	0.22	1.27	4.06	22	27	132	2.25	0.24
Cash Interest Paid	-	-	-	0.00	0.00	0.49	8.99	8.86

This table details how cash moves in and out of Adaptive Biotechnologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	141	-128	4.50	15	-21	-24	6.20	-11	-22	9.76
Net Cash From Operating Activities	-42	-30	-59	-24	-47	-27	-38	-17	-27	-12
Net Cash From Continuing Operating Activities	-42	-30	-59	-24	-47	-27	-38	-17	-27	-12
Net Income / (Loss) Continuing Operations	-45	-40	-58	-48	-50	-69	-48	-46	-32	-34
Consolidated Net Income / (Loss)	-45	-40	-58	-48	-50	-69	-48	-46	-32	-34
Depreciation Expense	4.96	4.86	5.00	5.23	5.34	4.96	4.79	4.58	4.16	4.02
Amortization Expense	0.84	-0.66	-1.19	-1.50	-2.27	-2.53	-2.22	-1.68	-1.58	-1.03
Non-Cash Adjustments To Reconcile Net Income	16	16	19	20	19	44	17	23	15	15
Changes in Operating Assets and Liabilities, net	-19	-10	-24	0.45	-19	-3.51	-10	2.83	-13	3.05
Net Cash From Investing Activities	58	-98	63	37	26	3.21	45	5.88	5.29	22
Net Cash From Continuing Investing Activities	58	-98	63	37	26	3.21	45	5.88	5.29	22
Purchase of Property, Plant & Equipment	-5.43	-2.54	-2.92	-3.70	-2.78	-1.30	-1.51	-1.73	-0.34	-0.08
Purchase of Investments	-29	-165	-89	-99	-119	-122	-53	-83	-63	-45
Sale and/or Maturity of Investments	92	70	155	140	148	127	100	90	69	67
Net Cash From Financing Activities	126	0.01	0.67	1.47	0.02	0.09	0.04	0.03	0.04	0.13
Net Cash From Continuing Financing Activities	126	0.01	0.67	1.47	0.02	0.09	0.04	0.03	0.04	0.13
Other Financing Activities, net	0.83	125	0.67	1.47	0.02	0.09	0.04	0.03	0.04	0.13
Cash Interest Paid	-	0.49	2.76	1.88	2.45	1.90	2.29	2.09	2.16	2.32

This table presents Adaptive Biotechnologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	333	912	1,116	923	857	661	539
Total Current Assets	181	613	727	403	562	410	284
Cash & Equivalents	55	97	123	139	90	65	48
Short-Term Investments	110	480	565	214	408	281	174
Accounts Receivable	4.81	13	10	17	40	38	42
Inventories, net	7.84	9.07	14	19	14	14	8.44
Prepaid Expenses	3.06	14	15	13	9.44	11	11
Plant, Property, & Equipment, net	19	60	40	85	83	68	49
Total Noncurrent Assets	133	239	350	435	211	183	207
Long-Term Investments	0.00	105	119	217	-	0.00	34
Goodwill	119	119	119	119	119	119	119
Intangible Assets	14	12	10	8.53	6.83	5.13	3.43
Other Noncurrent Operating Assets	0.25	2.92	102	91	85	59	51
Total Liabilities & Shareholders' Equity	333	912	1,116	923	857	661	539
Total Liabilities	30	341	373	319	393	353	337
Total Current Liabilities	23	78	105	114	110	88	98
Short-Term Debt	-	-	-	-	-	0.00	0.87
Accounts Payable	1.79	4.45	3.24	3.31	8.08	7.72	7.27
Accrued Expenses	2.56	4.37	13	9.34	12	8.60	8.16
Current Deferred Revenue	14	61	73	80	64	49	56
Current Employee Benefit Liabilities	4.64	8.12	12	16	16	14	16
Other Current Liabilities	-	0.00	3.53	5.06	9.23	9.38	10
Total Noncurrent Liabilities	7.14	263	268	205	283	265	239
Long-Term Debt	-	-	-	-	125	131	132
Noncurrent Deferred Revenue	6.81	226	164	99	59	45	27
Other Noncurrent Operating Liabilities	0.34	37	104	107	99	89	79
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-258	571	743	604	464	308	202
Total Preferred & Common Equity	-258	571	743	604	464	308	203
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-258	571	743	604	464	308	203
Common Stock	38	936	1,254	1,324	1,387	1,453	1,506
Retained Earnings	-296	-365	-512	-719	-919	-1,144	-1,304
Accumulated Other Comprehensive Income / (Loss)	-0.11	0.67	0.89	-1.14	-4.12	0.22	0.17
Noncontrolling Interest	-	-	0.00	0.11	-0.07	-0.12	-0.22

This table presents Adaptive Biotechnologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	884	791	765	718	620	585	559
Total Current Assets	564	501	477	435	374	352	308
Cash & Equivalents	218	95	109	89	71	60	38
Short-Term Investments	291	346	308	282	238	232	205
Accounts Receivable	27	31	32	31	42	36	41
Inventories, net	17	20	19	19	13	13	12
Prepaid Expenses	12	9.79	9.07	13	9.85	11	12
Plant, Property, & Equipment, net	87	81	79	77	65	55	51
Total Noncurrent Assets	233	209	208	206	178	178	199
Long-Term Investments	20	-	-	-	-	-	24
Goodwill	119	119	119	119	119	119	119
Intangible Assets	7.26	6.41	5.99	5.56	4.71	4.28	3.85
Other Noncurrent Operating Assets	87	83	83	81	54	55	52
Total Liabilities & Shareholders' Equity	884	791	765	718	620	585	559
Total Liabilities	396	368	369	356	346	343	335
Total Current Liabilities	104	90	95	93	83	88	88
Accounts Payable	4.16	6.33	9.16	4.48	12	9.87	7.35
Accrued Expenses	11	8.04	8.36	10	7.91	6.71	6.06
Current Deferred Revenue	68	60	58	55	47	52	52
Current Employee Benefit Liabilities	13	6.12	11	11	6.40	9.52	12
Other Current Liabilities	8.53	9.29	9.35	9.48	9.59	9.81	10
Total Noncurrent Liabilities	292	277	273	263	263	255	247
Long-Term Debt	-	-	-	127	132	132	133
Noncurrent Deferred Revenue	67	54	51	44	44	39	33
Other Noncurrent Operating Liabilities	225	224	222	92	87	84	82
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	488	424	396	362	275	241	224
Total Preferred & Common Equity	488	424	396	362	275	242	224
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	488	424	396	362	275	242	224
Common Stock	1,373	1,403	1,422	1,437	1,467	1,480	1,493
Retained Earnings	-879	-977	-1,025	-1,075	-1,192	-1,238	-1,270
Accumulated Other Comprehensive Income / (Loss)	-5.97	-1.91	-0.89	-0.25	-0.11	-0.18	0.50
Noncontrolling Interest	-0.03	-0.07	-0.07	-0.10	-0.15	-0.17	-0.20

This table displays calculated financial ratios and metrics derived from Adaptive Biotechnologies' official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	254.79%	52.83%	15.65%	56.88%	20.06%	-8.11%	5.10%
EBITDA Growth	0.00%	-134.60%	16.54%	-91.27%	-30.79%	4.93%	-19.86%	29.20%
EBIT Growth	0.00%	-123.75%	-57.55%	2.53%	-36.74%	4.20%	-13.41%	28.40%
NOPAT Growth	0.00%	-123.75%	21.22%	-94.94%	-36.74%	4.20%	-13.41%	28.40%
Net Income Growth	0.00%	-8.44%	-47.71%	-113.14%	-41.76%	3.34%	-12.45%	29.16%
EPS Growth	0.00%	-4.86%	72.48%	-9.90%	-33.33%	5.41%	-11.43%	30.77%
Operating Cash Flow Growth	0.00%	7.46%	736.73%	-172.87%	-28.76%	4.56%	15.02%	39.09%
Free Cash Flow Firm Growth	0.00%	0.00%	196.15%	-146.62%	-57.52%	18.96%	18.88%	36.92%
Invested Capital Growth	0.00%	0.00%	-140.39%	42.90%	153.36%	169.24%	1.40%	-13.75%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	107.05%	-24.10%	10.28%	-5.24%	0.94%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-13.96%	-8.58%	10.29%	-18.66%	19.96%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-15.10%	-9.06%	10.07%	-16.34%	18.64%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-15.10%	-9.06%	10.07%	-16.34%	18.64%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	8.03%	-34.79%	9.56%	-14.95%	18.30%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-211.00%	-8.03%	10.83%	-15.56%	19.40%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-9.43%	-9.55%	-7.82%	11.46%	1.94%	13.17%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-6.07%	-104.17%	46.06%	6.86%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	16.96%	77.24%	328.37%	-23.16%	-10.41%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	0.06%	64.67%	73.82%	77.10%	68.06%	68.75%	55.63%	59.72%
EBITDA Margin	-244.36%	-80.79%	-88.24%	-145.93%	-121.66%	-96.34%	-125.67%	-84.66%
Operating Margin	-283.48%	-89.39%	-92.15%	-155.33%	-135.39%	-108.03%	-133.33%	-90.83%
EBIT Margin	-283.48%	-89.39%	-92.15%	-155.33%	-135.39%	-108.03%	-133.33%	-90.83%
Profit (Net Income) Margin	-273.00%	-83.44%	-80.65%	-148.63%	-134.31%	-108.13%	-132.32%	-89.18%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.30%	93.35%	87.52%	95.69%	99.20%	100.09%	99.24%	98.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-50.58%	-66.84%	0.00%	0.00%	-223.93%	-172.93%	-132.04%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-72.99%	-128.25%	0.00%	0.00%	-211.15%	-150.38%	-104.97%
Return on Net Nonoperating Assets (RNNOA)	0.00%	19.89%	187.16%	0.00%	0.00%	186.41%	114.59%	69.55%
Return on Equity (ROE)	0.00%	-30.68%	7.46%	-22.25%	-30.77%	-37.52%	-58.34%	-62.49%
Cash Return on Invested Capital (CROIC)	0.00%	-1,002.31%	0.00%	0.00%	-718.96%	-315.60%	-174.32%	-117.27%
Operating Return on Assets (OROA)	0.00%	-29.91%	-12.59%	-15.07%	-20.49%	-22.49%	-29.92%	-27.08%
Return on Assets (ROA)	0.00%	-13.96%	-22.04%	-14.42%	-20.33%	-22.51%	-29.69%	-26.59%
Return on Common Equity (ROCE)	0.00%	26.16%	8.89%	-22.25%	-30.77%	-37.51%	-58.35%	-62.54%
Return on Equity Simple (ROE_SIMPLE)	0.00%	17.99%	-12.01%	-19.67%	-34.32%	-43.17%	-73.06%	-78.73%
Net Operating Profit after Tax (NOPAT)	-31	-70	-55	-107	-146	-140	-159	-114
NOPAT Margin	-198.44%	-62.57%	-64.50%	-108.73%	-94.77%	-75.62%	-93.33%	-63.58%
Net Nonoperating Expense Percent (NNEP)	0.00%	-12.08%	-2.71%	-5.27%	-8.86%	-12.78%	-22.56%	-27.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-23.77%	-36.21%	-33.89%
Cost of Revenue to Revenue	99.94%	35.33%	26.18%	22.90%	31.94%	31.25%	44.37%	40.28%
SG&A Expenses to Revenue	101.66%	36.67%	35.65%	50.35%	48.27%	47.77%	49.29%	40.68%
R&D to Revenue	203.93%	70.35%	83.11%	117.98%	92.22%	76.50%	71.72%	57.53%
Operating Expenses to Revenue	283.54%	154.05%	165.96%	232.43%	203.45%	176.78%	188.96%	150.55%
Earnings before Interest and Taxes (EBIT)	-44	-100	-157	-153	-209	-200	-227	-163
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-38	-90	-75	-144	-188	-179	-214	-152
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	6.51	10.88	6.56	2.35	2.30	4.36
Price to Tangible Book Value (P/TBV)	0.00	0.00	8.45	13.17	8.31	3.23	3.85	11.02
Price to Revenue (P/Rev)	19.12	5.39	43.73	82.20	25.66	5.90	4.17	4.94
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	5.05	0.00	0.00	100.01	7.89	5.33	9.55
Enterprise Value to Revenue (EV/Rev)	0.00	12.50	35.71	74.00	21.96	3.88	2.90	4.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	14.79	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	9.15	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.27	0.42	0.66
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.27	0.42	0.65
Financial Leverage	0.00	-0.55	-1.16	-1.13	-1.02	-0.88	-0.76	-0.66
Leverage Ratio	0.00	1.10	1.42	1.54	1.51	1.67	1.97	2.35
Compound Leverage Factor	0.00	1.03	1.25	1.48	1.50	1.67	1.95	2.31
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	21.27%	29.77%	39.69%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.26%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	21.27%	29.77%	39.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	370.51%	0.00%	0.00%	0.02%	-0.01%	-0.03%	-0.07%
Common Equity to Total Capital	0.00%	-85.26%	200.00%	100.00%	99.98%	78.74%	70.26%	60.37%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.70	-0.61	-0.88
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	2.09	1.01	0.81
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.70	-0.61	-0.87
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.89	-0.82	-1.17
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	2.66	1.36	1.08
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.89	-0.82	-1.16
Altman Z-Score	0.00	5.01	10.08	12.67	6.15	0.25	-1.51	-2.06
Noncontrolling Interest Sharing Ratio	0.00%	185.26%	64.19%	0.00%	0.01%	0.00%	-0.02%	-0.07%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	15.85	7.82	6.91	3.54	5.12	4.66	2.89
Quick Ratio	0.00	14.90	7.53	6.64	3.26	4.90	4.37	2.69
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-345	332	-155	-244	-197	-160	-101
Operating Cash Flow to CapEx	-1,574.44%	-1,024.26%	1,833.96%	-796.06%	-312.13%	-1,125.11%	-1,461.38%	-2,598.58%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-46.60	-11.61	-8.73
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-43.40	-11.33	-8.22
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-47.26	-12.10	-8.54
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.17	0.14	0.10	0.15	0.21	0.22	0.30
Accounts Receivable Turnover	0.00	11.58	9.73	8.66	11.24	6.45	4.36	4.49
Inventory Turnover	0.00	2.51	2.63	1.95	2.96	3.44	5.23	6.30
Fixed Asset Turnover	0.00	2.91	2.14	1.97	2.47	2.20	2.25	3.06
Accounts Payable Turnover	0.00	10.97	7.13	5.86	15.07	10.17	9.56	9.62
Days Sales Outstanding (DSO)	0.00	31.52	37.51	42.15	32.46	56.60	83.63	81.28
Days Inventory Outstanding (DIO)	0.00	145.46	138.53	187.38	123.36	106.26	69.81	57.95
Days Payable Outstanding (DPO)	0.00	33.27	51.18	62.29	24.22	35.90	38.17	37.94
Cash Conversion Cycle (CCC)	0.00	143.70	124.86	167.24	131.60	126.95	115.27	101.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	275	-111	-64	34	91	93	80
Invested Capital Turnover	0.00	0.81	1.04	-1.13	-10.42	2.96	1.85	2.08
Increase / (Decrease) in Invested Capital	0.00	275	-387	48	97	57	1.28	-13
Enterprise Value (EV)	0.00	696	3,038	7,281	3,390	720	494	762
Market Capitalization	300	300	3,720	8,087	3,960	1,093	709	885
Book Value per Share	$0.00	($20.44)	$4.59	$5.43	$4.28	$3.25	$2.13	$1.37
Tangible Book Value per Share	$0.00	($61.87)	$3.54	$4.49	$3.38	$2.37	$1.27	$0.54
Total Capital	0.00	605	571	743	604	589	439	336
Total Debt	0.00	0.00	0.00	0.00	0.00	125	131	133
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	125	131	132
Net Debt	0.00	-330	-682	-807	-570	-373	-216	-123
Capital Expenditures (CapEx)	2.21	13	11	19	62	16	11	3.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-14	-42	-67	-64	-46	-24	-36
Debt-free Net Working Capital (DFNWC)	0.00	158	534	622	289	452	322	187
Net Working Capital (NWC)	0.00	316	534	622	289	452	322	186
Net Nonoperating Expense (NNE)	12	23	14	39	61	60	66	46
Net Nonoperating Obligations (NNO)	0.00	-330	-682	-807	-570	-373	-216	-123
Total Depreciation and Amortization (D&A)	6.14	9.57	3.33	9.25	21	22	13	11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-25.51%	-49.95%	-67.65%	-41.54%	-24.74%	-14.23%	-19.97%
Debt-free Net Working Capital to Revenue	0.00%	283.70%	628.15%	631.94%	187.21%	244.11%	189.21%	104.25%
Net Working Capital to Revenue	0.00%	283.70%	1,914.20%	631.94%	187.21%	244.11%	189.21%	103.77%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.50)	($3.67)	($1.01)	($1.11)	($1.48)	($1.40)	($1.56)	($1.08)
Adjusted Weighted Average Basic Shares Outstanding	12.20M	12.63M	126.32M	139.22M	141.58M	142.52M	144.38M	147.10M
Adjusted Diluted Earnings per Share	($3.50)	($3.67)	($1.01)	($1.11)	($1.48)	($1.40)	($1.56)	($1.08)
Adjusted Weighted Average Diluted Shares Outstanding	12.20M	12.63M	126.32M	139.22M	141.58M	142.52M	144.38M	147.10M
Adjusted Basic & Diluted Earnings per Share	($3.50)	($3.67)	($1.01)	($1.11)	($1.48)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.20M	12.63M	69.17M	131.22M	140.35M	143.23M	145.09M	148.58M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-70	-55	-107	-146	-140	-141	-109
Normalized NOPAT Margin	-194.69%	-62.57%	-64.50%	-108.73%	-94.77%	-75.62%	-82.88%	-60.76%
Pre Tax Income Margin	-273.00%	-83.44%	-80.65%	-148.63%	-134.31%	-108.13%	-132.32%	-89.18%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-47.24	-16.45	-14.04
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-33.07	-11.52	-9.83
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-51.09	-17.23	-14.35
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-36.92	-12.29	-10.14
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-14.54%	-0.22%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Adaptive Biotechnologies' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.19%	45.53%	-2.52%	12.06%	-20.72%	-17.06%	11.23%	-11.72%	22.46%	3.66%
EBITDA Growth	22.30%	36.93%	6.60%	5.71%	-20.82%	-96.19%	13.47%	-0.75%	37.26%	55.06%
EBIT Growth	19.34%	36.38%	9.31%	8.92%	-12.16%	-81.36%	14.74%	1.05%	35.96%	52.39%
NOPAT Growth	19.34%	36.38%	9.31%	8.92%	-12.16%	-81.36%	14.74%	1.05%	35.96%	52.39%
Net Income Growth	19.07%	34.53%	8.12%	8.20%	-11.05%	-72.94%	17.62%	3.27%	36.22%	51.46%
EPS Growth	20.00%	38.64%	9.09%	10.81%	-9.38%	-77.78%	17.50%	6.06%	37.14%	54.17%
Operating Cash Flow Growth	2.38%	44.23%	8.22%	49.95%	-10.08%	10.28%	35.16%	26.55%	42.03%	53.62%
Free Cash Flow Firm Growth	120.20%	39.66%	125.26%	155.09%	-818.56%	39.83%	-594.78%	-345.34%	104.34%	78.52%
Invested Capital Growth	-308.97%	169.24%	-131.84%	-131.43%	401.35%	1.40%	661.72%	483.92%	-26.03%	-13.75%
Revenue Q/Q Growth	9.55%	15.40%	-31.80%	29.96%	-22.50%	20.74%	-8.54%	3.15%	7.51%	2.21%
EBITDA Q/Q Growth	15.22%	11.74%	-52.58%	17.42%	-8.64%	-43.32%	32.70%	3.85%	32.34%	-2.66%
EBIT Q/Q Growth	13.47%	13.75%	-45.95%	16.39%	-6.56%	-39.47%	31.39%	2.96%	31.04%	-3.69%
NOPAT Q/Q Growth	13.47%	13.75%	-45.95%	16.39%	-6.56%	-39.47%	31.39%	2.96%	31.04%	-3.69%
Net Income Q/Q Growth	12.99%	11.36%	-43.64%	17.14%	-5.26%	-38.03%	31.57%	2.70%	30.60%	-5.05%
EPS Q/Q Growth	13.51%	15.63%	-48.15%	17.50%	-6.06%	-37.14%	31.25%	6.06%	29.03%	0.00%
Operating Cash Flow Q/Q Growth	9.89%	29.21%	-97.05%	60.18%	-98.18%	42.31%	-42.41%	54.88%	-56.42%	53.85%
Free Cash Flow Firm Q/Q Growth	127.11%	-410.78%	134.54%	89.28%	-453.64%	73.98%	-184.04%	6.15%	106.25%	-228.83%
Invested Capital Q/Q Growth	-159.07%	328.37%	-118.35%	-27.00%	666.37%	-23.16%	1.63%	-13.20%	9.12%	-10.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	68.83%	69.95%	50.38%	63.39%	48.98%	57.16%	56.89%	55.27%	64.11%	61.98%
EBITDA Margin	-82.87%	-63.38%	-141.79%	-90.10%	-126.30%	-149.91%	-110.31%	-102.83%	-64.71%	-65.00%
Operating Margin	-94.98%	-70.99%	-151.92%	-97.74%	-134.38%	-155.22%	-116.45%	-109.56%	-70.27%	-71.30%
EBIT Margin	-94.98%	-70.99%	-151.92%	-97.74%	-134.38%	-155.22%	-116.45%	-109.56%	-70.27%	-71.30%
Profit (Net Income) Margin	-94.75%	-72.77%	-153.27%	-97.72%	-132.72%	-151.73%	-113.52%	-107.08%	-69.12%	-71.04%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.75%	102.51%	100.89%	99.99%	98.76%	97.75%	97.48%	97.74%	98.36%	99.65%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-147.15%	-1,093.91%	-559.27%	-420.13%	-201.33%	-368.01%	-428.79%	-83.25%	-103.64%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-144.45%	-1,090.15%	-555.97%	-416.32%	-194.62%	-363.70%	-424.24%	-78.33%	-97.72%
Return on Net Nonoperating Assets (RNNOA)	0.00%	127.53%	1,050.17%	527.76%	376.88%	148.31%	323.46%	384.06%	50.28%	64.74%
Return on Equity (ROE)	-38.89%	-19.63%	-43.74%	-31.51%	-43.25%	-53.01%	-44.55%	-44.73%	-32.97%	-38.90%
Cash Return on Invested Capital (CROIC)	0.00%	-315.60%	0.00%	0.00%	-246.62%	-174.32%	-280.51%	-313.07%	-103.57%	-117.27%
Operating Return on Assets (OROA)	-17.01%	-14.78%	-33.95%	-23.59%	-30.15%	-34.83%	-28.79%	-27.40%	-19.52%	-21.26%
Return on Assets (ROA)	-16.97%	-15.15%	-34.25%	-23.58%	-29.78%	-34.04%	-28.06%	-26.78%	-19.20%	-21.18%
Return on Common Equity (ROCE)	-38.89%	-19.63%	-43.74%	-31.51%	-43.25%	-53.03%	-44.57%	-44.75%	-32.98%	-38.93%
Return on Equity Simple (ROE_SIMPLE)	-45.42%	0.00%	-46.05%	-48.23%	-54.19%	0.00%	-78.26%	-88.40%	-87.30%	0.00%
Net Operating Profit after Tax (NOPAT)	-32	-27	-40	-33	-36	-50	-34	-33	-23	-24
NOPAT Margin	-66.49%	-49.69%	-106.34%	-68.41%	-94.07%	-108.66%	-81.52%	-76.69%	-49.19%	-49.91%
Net Nonoperating Expense Percent (NNEP)	-2.33%	-2.70%	-3.75%	-3.30%	-3.81%	-6.70%	-4.31%	-4.55%	-4.93%	-5.93%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.65%	-	-	-	-11.33%	-	-	-	-7.05%
Cost of Revenue to Revenue	31.17%	30.05%	49.62%	36.61%	51.02%	42.84%	43.11%	44.73%	35.89%	38.02%
SG&A Expenses to Revenue	43.39%	40.63%	55.33%	45.58%	52.94%	45.27%	46.80%	41.43%	37.17%	38.05%
R&D to Revenue	74.55%	56.56%	86.60%	65.89%	75.25%	62.79%	72.23%	58.70%	52.04%	48.87%
Operating Expenses to Revenue	163.82%	140.94%	202.30%	161.13%	183.36%	212.38%	173.34%	164.83%	134.38%	133.28%
Earnings before Interest and Taxes (EBIT)	-45	-39	-57	-48	-51	-71	-49	-47	-33	-34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-40	-35	-53	-44	-48	-69	-46	-44	-30	-31
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.09	2.35	2.98	2.45	2.18	2.30	1.69	2.21	3.37	4.36
Price to Tangible Book Value (P/TBV)	2.81	3.23	4.23	3.57	3.32	3.85	3.08	4.51	7.48	11.02
Price to Revenue (P/Rev)	6.05	5.90	6.86	5.11	4.39	4.17	2.67	3.16	4.26	4.94
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	7.89	0.00	0.00	4.54	5.33	3.07	4.58	6.96	9.55
Enterprise Value to Revenue (EV/Rev)	2.91	3.88	4.47	2.91	3.04	2.90	1.65	2.21	3.50	4.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.27	0.00	0.00	0.36	0.42	0.48	0.55	0.59	0.66
Long-Term Debt to Equity	0.00	0.27	0.00	0.00	0.35	0.42	0.48	0.55	0.59	0.65
Financial Leverage	-1.02	-0.88	-0.96	-0.95	-0.91	-0.76	-0.89	-0.91	-0.64	-0.66
Leverage Ratio	1.65	1.67	1.69	1.72	1.89	1.97	2.02	2.12	2.18	2.35
Compound Leverage Factor	1.64	1.71	1.70	1.72	1.86	1.92	1.97	2.07	2.15	2.34
Debt to Total Capital	0.00%	21.27%	0.00%	0.00%	26.43%	29.77%	32.38%	35.36%	37.25%	39.69%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.65%	0.00%	0.00%	0.00%	0.00%	0.26%
Long-Term Debt to Total Capital	0.00%	21.27%	0.00%	0.00%	25.78%	29.77%	32.38%	35.36%	37.25%	39.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.01%	-0.01%	-0.02%	-0.02%	-0.02%	-0.03%	-0.04%	-0.05%	-0.06%	-0.07%
Common Equity to Total Capital	100.01%	78.74%	100.02%	100.02%	73.59%	70.26%	67.66%	64.68%	62.81%	60.37%
Debt to EBITDA	0.00	-0.70	0.00	0.00	-0.72	-0.61	-0.64	-0.64	-0.70	-0.88
Net Debt to EBITDA	0.00	2.09	0.00	0.00	1.34	1.01	0.86	0.77	0.71	0.81
Long-Term Debt to EBITDA	0.00	-0.70	0.00	0.00	-0.70	-0.61	-0.64	-0.64	-0.70	-0.87
Debt to NOPAT	0.00	-0.89	0.00	0.00	-0.95	-0.82	-0.86	-0.87	-0.95	-1.17
Net Debt to NOPAT	0.00	2.66	0.00	0.00	1.77	1.36	1.16	1.05	0.96	1.08
Long-Term Debt to NOPAT	0.00	-0.89	0.00	0.00	-0.93	-0.82	-0.86	-0.87	-0.95	-1.16
Altman Z-Score	0.79	0.87	0.95	0.34	-0.18	-0.73	-1.30	-1.47	-1.23	-1.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	-0.01%	-0.01%	-0.02%	-0.03%	-0.04%	-0.05%	-0.07%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.43	5.12	5.56	5.00	4.67	4.66	4.51	3.99	3.52	2.89
Quick Ratio	5.14	4.90	5.23	4.71	4.31	4.37	4.23	3.72	3.24	2.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	27	-85	29	55	-196	-51	-145	-136	8.51	-11
Operating Cash Flow to CapEx	-780.71%	-1,180.92%	-2,022.98%	-637.17%	-1,680.49%	-2,074.88%	-2,538.25%	-1,000.75%	-7,867.73%	-15,613.75%
Free Cash Flow to Firm to Interest Expense	41.78	-23.65	8.30	15.38	-53.69	-16.94	-48.42	-50.45	2.89	-3.71
Operating Cash Flow to Interest Expense	-64.94	-8.37	-16.75	-6.53	-12.78	-8.94	-12.81	-6.42	-9.21	-4.23
Operating Cash Flow Less CapEx to Interest Expense	-73.26	-9.08	-17.58	-7.56	-13.54	-9.37	-13.32	-7.06	-9.33	-4.26
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.18	0.21	0.22	0.24	0.22	0.22	0.25	0.25	0.28	0.30
Accounts Receivable Turnover	7.70	6.45	6.89	6.86	6.22	4.36	4.78	5.03	4.92	4.49
Inventory Turnover	3.13	3.44	3.10	3.61	3.94	5.23	4.52	4.74	4.68	6.30
Fixed Asset Turnover	1.93	2.20	2.20	2.28	2.20	2.25	2.38	2.50	2.77	3.06
Accounts Payable Turnover	8.97	10.17	10.32	11.46	16.78	9.56	8.10	8.02	12.45	9.62
Days Sales Outstanding (DSO)	47.43	56.60	52.96	53.19	58.66	83.63	76.34	72.62	74.14	81.28
Days Inventory Outstanding (DIO)	116.61	106.26	117.67	101.15	92.69	69.81	80.78	76.93	77.92	57.95
Days Payable Outstanding (DPO)	40.70	35.90	35.38	31.85	21.76	38.17	45.07	45.50	29.32	37.94
Cash Conversion Cycle (CCC)	123.35	126.95	135.24	122.49	129.60	115.27	112.05	104.05	122.74	101.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-40	91	-17	-21	120	93	94	82	89	80
Invested Capital Turnover	-16.13	2.96	10.29	8.17	4.47	1.85	4.51	5.59	1.69	2.08
Increase / (Decrease) in Invested Capital	-59	57	-69	-89	160	1.28	111	103	-31	-13
Enterprise Value (EV)	489	720	824	551	547	494	288	374	620	762
Market Capitalization	1,017	1,093	1,265	968	788	709	466	533	755	885
Book Value per Share	$3.41	$3.25	$2.96	$2.74	$2.50	$2.13	$1.89	$1.64	$1.52	$1.37
Tangible Book Value per Share	$2.53	$2.37	$2.09	$1.88	$1.64	$1.27	$1.04	$0.80	$0.68	$0.54
Total Capital	488	589	424	396	492	439	406	374	356	336
Total Debt	0.00	125	0.00	0.00	130	131	132	132	133	133
Total Long-Term Debt	0.00	125	0.00	0.00	127	131	132	132	133	132
Net Debt	-528	-373	-441	-417	-241	-216	-177	-160	-134	-123
Capital Expenditures (CapEx)	5.43	2.54	2.92	3.70	2.78	1.30	1.51	1.73	0.34	0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-48	-46	-29	-36	-26	-24	-18	-28	-23	-36
Debt-free Net Working Capital (DFNWC)	460	452	411	381	345	322	291	263	221	187
Net Working Capital (NWC)	460	452	411	381	342	322	291	263	221	186
Net Nonoperating Expense (NNE)	14	13	18	14	15	20	13	13	9.25	10
Net Nonoperating Obligations (NNO)	-528	-373	-441	-417	-241	-216	-181	-160	-134	-123
Total Depreciation and Amortization (D&A)	5.79	4.20	3.81	3.74	3.07	2.43	2.57	2.90	2.58	2.99
Debt-free, Cash-free Net Working Capital to Revenue	-28.40%	-24.74%	-15.98%	-18.86%	-14.47%	-14.23%	-10.19%	-16.86%	-12.75%	-19.97%
Debt-free Net Working Capital to Revenue	273.96%	244.11%	223.09%	201.20%	192.07%	189.21%	166.81%	156.09%	124.50%	104.25%
Net Working Capital to Revenue	273.96%	244.11%	223.09%	201.20%	190.29%	189.21%	166.81%	156.09%	124.50%	103.77%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.32)	($0.27)	($0.40)	($0.33)	($0.35)	($0.48)	($0.33)	($0.31)	($0.22)	($0.22)
Adjusted Weighted Average Basic Shares Outstanding	142.93M	142.52M	143.51M	144.40M	144.70M	144.38M	145.79M	147.41M	147.52M	147.10M
Adjusted Diluted Earnings per Share	($0.32)	($0.27)	($0.40)	($0.33)	($0.35)	($0.48)	($0.33)	($0.31)	($0.22)	($0.22)
Adjusted Weighted Average Diluted Shares Outstanding	142.93M	142.52M	143.51M	144.40M	144.70M	144.38M	145.79M	147.41M	147.52M	147.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	143.01M	143.23M	144.31M	144.65M	144.77M	145.09M	147.37M	147.47M	147.58M	148.58M
Normalized Net Operating Profit after Tax (NOPAT)	-32	-27	-40	-33	-36	-32	-34	-28	-23	-24
Normalized NOPAT Margin	-66.49%	-49.69%	-106.34%	-68.41%	-94.07%	-69.78%	-81.52%	-65.01%	-49.19%	-49.91%
Pre Tax Income Margin	-94.75%	-72.77%	-153.27%	-97.72%	-132.72%	-151.73%	-113.52%	-107.08%	-69.12%	-71.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-69.57	-10.93	-16.20	-13.26	-13.95	-23.60	-16.29	-17.55	-11.10	-11.46
NOPAT to Interest Expense	-48.70	-7.65	-11.34	-9.29	-9.77	-16.52	-11.40	-12.29	-7.77	-8.02
EBIT Less CapEx to Interest Expense	-77.89	-11.64	-17.03	-14.29	-14.71	-24.03	-16.80	-18.19	-11.22	-11.49
NOPAT Less CapEx to Interest Expense	-57.02	-8.36	-12.17	-10.31	-10.53	-16.95	-11.91	-12.93	-7.89	-8.05
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Adaptive Biotechnologies' Financials

When does Adaptive Biotechnologies's financial year end?

According to the most recent income statement we have on file, Adaptive Biotechnologies' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Adaptive Biotechnologies' net income changed over the last 7 years?

Adaptive Biotechnologies' net income appears to be on an upward trend, with a most recent value of -$159.60 million in 2024, rising from -$42.83 million in 2017. The previous period was -$225.30 million in 2023. Find out what analysts predict for Adaptive Biotechnologies in the coming months.

What is Adaptive Biotechnologies's operating income?

Adaptive Biotechnologies's total operating income in 2024 was -$162.55 million, based on the following breakdown:

Total Gross Profit: $106.88 million
Total Operating Expenses: $269.43 million

How has Adaptive Biotechnologies revenue changed over the last 7 years?

Over the last 7 years, Adaptive Biotechnologies' total revenue changed from $15.69 million in 2017 to $178.96 million in 2024, a change of 1,040.7%.

How much debt does Adaptive Biotechnologies have?

Adaptive Biotechnologies' total liabilities were at $336.89 million at the end of 2024, a 4.5% decrease from 2023, and a 1,025.1% increase since 2018.

How much cash does Adaptive Biotechnologies have?

In the past 6 years, Adaptive Biotechnologies' cash and equivalents has ranged from $47.92 million in 2024 to $139.07 million in 2021, and is currently $47.92 million as of their latest financial filing in 2024.

How has Adaptive Biotechnologies' book value per share changed over the last 7 years?

Over the last 7 years, Adaptive Biotechnologies' book value per share changed from 0.00 in 2017 to 1.37 in 2024, a change of 137.4%.

Related Companies

This page (NASDAQ:ADPT) was last updated on 5/8/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Financials

Frequently Asked Questions About Adaptive Biotechnologies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Financials

Annual Income Statements for Adaptive Biotechnologies

Quarterly Income Statements for Adaptive Biotechnologies

Annual Cash Flow Statements for Adaptive Biotechnologies

Quarterly Cash Flow Statements for Adaptive Biotechnologies

Annual Balance Sheets for Adaptive Biotechnologies

Quarterly Balance Sheets for Adaptive Biotechnologies

Annual Metrics and Ratios for Adaptive Biotechnologies

Quarterly Metrics and Ratios for Adaptive Biotechnologies

Frequently Asked Questions About Adaptive Biotechnologies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools